Pioneering the discovery and development of selective translation regulators.
eFFECTOR Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
eFFECTOR is built on significant chemical and biological expertise. Through the fusion of these two disciplines, we can pharmaceutically control the regulation of messenger RNA (mRNA) translation. eFFECTOR believes that its expertise in these two disciplines gives the company a key advantage in the emerging field of selective translation regulator therapeutics.
Learn more about eFFECTOR’s platform to identify selective regulators of translation and develop drugs against new targets for therapeutic intervention.
11180 Roselle Street
San Diego, CA 92121